OBJECTIVES: In this study, we evaluate the outcomes of salvage cryotherapy for locally recurrent prostate cancer within the COLD (cryo online data) Registry. Furthermore, we assess the results of salvage cryotherapy (with intermediate follow-up) stratified by pre-treatment prostate-specific antigen (PSA) levels to determine which patients may best be suited for treatment. METHODS: The COLD registry was developed as a prospective, centrally collected database among patients undergoing salvage cryoablation for locally recurrent prostate cancer following primary prostate radiotherapy with curative intent. Of the patients undergoing salvage cryotherapy (without neoadjuvant hormonal ablative therapy), complete medical records were available in 156 patients, with their mean follow-up being 3.8 years (0.9-12.7 years). The treatment outcomes of salvage cryotherapy were assessed using the Phoenix definition (nadir PSA + 2 ng/ml) of biochemical failure. RESULTS: Of our entire study population, the biochemical disease-free survival (bDFS) rates at 1, 2, and 3 years were 89.0, 73.7, and 66.7%, respectively. Stratification of our patients into two subgroups is based on their pre-treatment total serum PSA values <5 and ≥5 ng/ml, and bDFS rates at 3 years for these two subgroups were 78.3 and 52.9%, respectively. A Kaplan-Meier analysis of bDFS stratified by these same pre-treatment PSA values revealed that the subset of patients with a PSA ≥ 5 ng/ml had statistically significant poorer bDFS rates (P = 0.01). CONCLUSIONS: Salvage prostate cryotherapy is a potentially curative local salvage therapy. The importance of early referral when patients have a pre-treatment PSA < 5 ng/ml is essential to optimize treatment outcomes.
OBJECTIVES: In this study, we evaluate the outcomes of salvage cryotherapy for locally recurrent prostate cancer within the COLD (cryo online data) Registry. Furthermore, we assess the results of salvage cryotherapy (with intermediate follow-up) stratified by pre-treatment prostate-specific antigen (PSA) levels to determine which patients may best be suited for treatment. METHODS: The COLD registry was developed as a prospective, centrally collected database among patients undergoing salvage cryoablation for locally recurrent prostate cancer following primary prostate radiotherapy with curative intent. Of the patients undergoing salvage cryotherapy (without neoadjuvant hormonal ablative therapy), complete medical records were available in 156 patients, with their mean follow-up being 3.8 years (0.9-12.7 years). The treatment outcomes of salvage cryotherapy were assessed using the Phoenix definition (nadir PSA + 2 ng/ml) of biochemical failure. RESULTS: Of our entire study population, the biochemical disease-free survival (bDFS) rates at 1, 2, and 3 years were 89.0, 73.7, and 66.7%, respectively. Stratification of our patients into two subgroups is based on their pre-treatment total serum PSA values <5 and ≥5 ng/ml, and bDFS rates at 3 years for these two subgroups were 78.3 and 52.9%, respectively. A Kaplan-Meier analysis of bDFS stratified by these same pre-treatment PSA values revealed that the subset of patients with a PSA ≥ 5 ng/ml had statistically significant poorer bDFS rates (P = 0.01). CONCLUSIONS: Salvage prostate cryotherapy is a potentially curative local salvage therapy. The importance of early referral when patients have a pre-treatment PSA < 5 ng/ml is essential to optimize treatment outcomes.
Authors: Louis L Pisters; Dan Leibovici; Michael Blute; Horst Zincke; Thomas J Sebo; Jeffrey M Slezak; Jonathan Izawa; John F Ward; Shellie M Scott; Lydia Madsen; Philippe E Spiess; Bradley C Leibovich Journal: J Urol Date: 2009-06-13 Impact factor: 7.450
Authors: Jonathan I Izawa; Lydia T Madsen; Shellie M Scott; Jean-Paul Tran; Edward J McGuire; Andrew C Von Eschenbach; Louis L Pisters Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: Philippe E Spiess; Andrew K Lee; Dan Leibovici; Xuemei Wang; Kim-Anh Do; Louis L Pisters Journal: Cancer Date: 2006-07-15 Impact factor: 6.860
Authors: Philippe E Spiess; Aaron E Katz; Joseph L Chin; Duke Bahn; Jeffrey K Cohen; Katsuto Shinohara; Mike Hernandez; Julie Bossier; Wassim Kassouf; Louis L Pisters Journal: BJU Int Date: 2009-11-17 Impact factor: 5.588
Authors: J G Baust; J C Bischof; S Jiang-Hughes; T J Polascik; D B Rukstalis; A A Gage; J M Baust Journal: Prostate Cancer Prostatic Dis Date: 2015-01-27 Impact factor: 5.554
Authors: Juanita Crook; Joseph P Rodgers; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Albert D Murtha; Eric Vigneault; Joelle Helou; Jeff M Michalski; Mack Roach; David Beyer; Ashesh B Jani; Eric M Horwitz; Adam Raben; Stephanie Pugh; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-03 Impact factor: 7.038
Authors: O Pons-Llanas; J Burgos-Burgos; S Roldan-Ortega; A Conde-Moreno; F Celada-Alvarez; J C Ruiz-Martinez; F Lliso-Valverde; A Tormo-Micó; J Perez-Calatayud; J López-Torrecilla Journal: Rep Pract Oncol Radiother Date: 2020-07-05
Authors: John M Baust; Anthony Robilotto; Kristi K Snyder; Kimberly Santucci; Jennie Stewart; Robert Van Buskirk; John G Baust Journal: Technol Cancer Res Treat Date: 2017-05-17
Authors: M Salji; R Jones; J Paul; F Birrell; J Dixon-Hughes; C Hutchison; T E B Johansen; D Greene; N Parr; H Y Leung Journal: Br J Cancer Date: 2014-06-19 Impact factor: 7.640